Sun Pharmaceutical concludes Opiates business acquisition in Australia

01 Sep 2015 Evaluate

Sun Pharmaceutical Industries has begun the integration of its Opiates business in Australia following the successful completion of this acquisition from GSK (announced in March 2015). This acquisition fortifies Sun Pharma’s global position with two Opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.

Sun Pharma now offers a rich basket of Opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialized team to drive business growth.

The Opiates acquisition allows Sun Pharma to significantly expand its narcotics raw material (NRM) market share; enhance Opiate Alkaloids portfolio and depth in Global opiates market and strengthen its strategic position in the global Opiates business.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.



Sun Pharma Inds. Share Price

1720.40 0.65 (0.04%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×